Skip to main content

Peer Review reports

From: Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Original Submission
31 Aug 2017 Submitted Original manuscript
31 Oct 2017 Author responded Author comments - Chiara Zecca
Resubmission - Version 2
31 Oct 2017 Submitted Manuscript version 2
7 Jan 2018 Reviewed Reviewer Report - luca prosperini
22 May 2018 Reviewed Reviewer Report - Alexey Boiko
14 Aug 2018 Author responded Author comments - Chiara Zecca
Resubmission - Version 3
14 Aug 2018 Submitted Manuscript version 3
16 Jan 2019 Reviewed Reviewer Report - luca prosperini
5 May 2019 Reviewed Reviewer Report - Ingo Kleiter
5 Jun 2019 Author responded Author comments - Chiara Zecca
Resubmission - Version 4
5 Jun 2019 Submitted Manuscript version 4
9 Jun 2019 Reviewed Reviewer Report - Ingo Kleiter
25 Jun 2019 Author responded Author comments - Chiara Zecca
Resubmission - Version 5
25 Jun 2019 Submitted Manuscript version 5
26 Jun 2019 Author responded Author comments - Chiara Zecca
Resubmission - Version 6
26 Jun 2019 Submitted Manuscript version 6
Publishing
27 Jun 2019 Editorially accepted
12 Jul 2019 Article published 10.1186/s12883-019-1383-6

You can find further information about peer review here.

Back to article page